razoxane has been researched along with Carcinoma, Small Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasinoff, BB; Hofland, KF; Jensen, PB; Langer, SW; Schroeder, PE; Sehested, M | 1 |
| Byfield, JE; Clamon, GH; Corder, MP; Herbst, KD; Leimert, JT; Platz, CE; Tewfik, HH | 1 |
| Falck, J; Jensen, LH; Jensen, PB; Nitiss, JL; Roerth, M; Rose, A; Sehested, M; Wessel, I | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Corniere, A; Sehested, M; Sorensen, TK; Wessel, I | 1 |
| Bush, H; Hellmann, K; James, SE; Spittle, MF | 1 |
3 trial(s) available for razoxane and Carcinoma, Small Cell
| Article | Year |
|---|---|
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carcinoma, Small Cell; Catheters, Indwelling; Chromatography, High Pressure Liquid; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Razoxane | 2004 |
Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Blood Cell Count; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperazines; Pneumonia; Radiation Injuries; Random Allocation; Razoxane | 1984 |
Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus.
Topics: Bronchial Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Esophagitis; Humans; Leukopenia; Piperazines; Radiation Injuries; Radiotherapy, High-Energy; Razoxane | 1979 |
2 other study(ies) available for razoxane and Carcinoma, Small Cell
| Article | Year |
|---|---|
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Catalysis; CHO Cells; Consensus Sequence; Cricetinae; Cricetulus; DNA Damage; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Protein Isoforms; Razoxane; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1999 |
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Drug Resistance, Neoplasm; Genotype; Humans; Lung Neoplasms; Mutation; Protein Binding; Razoxane; Saccharomyces cerevisiae; Transformation, Genetic; Tumor Cells, Cultured | 2002 |